Peptide therapy TikTok claims: what the science actually supports

What did @justagrownwoman actually say?

She's five weeks into self-administering SS-31, dosing somewhere between one and five milligrams roughly five days a week, specifically hoping to improve age-related eye changes. She reported that light sensitivity and blue light discomfort seem reduced and that her eyes "can actually focus on light a little bit better." She was honest that her near-vision presbyopia hasn't budged yet, and she openly called herself her own "freaking clinical trial." That level of self-awareness is actually refreshing on a platform that usually skips the caveats entirely.

She's not claiming a cure. She's logging subjective changes across a defined timeline, planning three months total, and she's explicitly framing this as anecdotal. The problem isn't her attitude. The problem is that the compound she's experimenting with is not well-characterized in humans for the application she's targeting, and her dosing range is unusually wide.

Does the science back this up?

Partially, and only in a very specific mechanistic sense. SS-31 (also called elamipretide or Szeto-Schiller peptide 31) is a mitochondria-targeting antioxidant peptide that binds cardiolipin on the inner mitochondrial membrane. Retinal cells, particularly photoreceptors and retinal ganglion cells, are among the most mitochondria-dense cells in the body, which is why researchers have looked at SS-31 in ocular contexts.

Chakrabarti et al. (2013, PLOS ONE) demonstrated SS-31 reduced oxidative stress in retinal pigment epithelial cells under metabolic stress in vitro. Bharat et al. (2020, Redox Biology) showed SS-31 preserved mitochondrial function in aging retinal tissue in mouse models. Importantly, a Phase 2 clinical trial by Steele et al. (2020, JAMA Ophthalmology) tested elamipretide for dry age-related macular degeneration and found modest improvements in some functional endpoints, though results were mixed and the trial did not achieve all primary endpoints. There is no published human data on SS-31 specifically for presbyopia or generalized light sensitivity reduction.

What did they get wrong (or right)?

She got the mechanistic rationale roughly right. Mitochondrial dysfunction does contribute to age-related retinal changes, and SS-31's mechanism of action in that tissue is biologically plausible. That's not nothing. But she conflates two very different problems: photoreceptor-level oxidative stress (where SS-31 has some science behind it) and presbyopia, which is a structural problem involving lens elasticity loss, not a mitochondrial disease. SS-31 has no known mechanism for reversing lens stiffening. Expecting it to fix near-vision blur is a category error.

The dosing range she describes, one to five milligrams per dose, is a fivefold spread. That's not a protocol. The elamipretide trials in AMD used 1.5 mg/day subcutaneous injection. Self-titrating across that range without clinical monitoring means she genuinely doesn't know what dose she's receiving on any given day, which makes her self-reported outcomes even harder to interpret. Her subjective light sensitivity improvement is interesting, but it could just as easily reflect screen habit changes, hydration, sleep, or placebo response over five weeks.

What should you actually know?

SS-31 is a legitimate research compound with a coherent mechanism. It is not approved by the FDA for any indication as of 2024. The clinical trial history is real but limited and mixed. If you're considering it for an eye-related condition, you need an ophthalmologist in the loop, not just a telehealth peptide prescription. Retinal and macular conditions can progress silently, and tracking outcomes by subjective feel is genuinely insufficient for anything involving vision.

The "own clinical trial" framing is charming, but real clinical trials have control conditions, objective endpoints like best-corrected visual acuity and optical coherence tomography imaging, and independent monitoring. Subjective reports of feeling less bothered by screens over five weeks do not constitute evidence that SS-31 is working, though they also don't prove it isn't. The honest answer is that she simply cannot know yet, and neither can we from this video. Anyone using this compound should be doing so under medical supervision with baseline and follow-up objective measurements, not just checking in on TikTok.